RecruitingACTRN12620001138976

Effectiveness of Hematoma block in acute pain management and closed reduction of fractures in children presenting to DHQ Kohat: An exploratory RCT


Sponsor

Khalid Rehman

Enrollment

150 participants

Start Date

Nov 12, 2019

Study Type

Interventional

Conditions

Summary

Hematoma block and Intravenous analgesia are both simple options, as none of these techniques require expertise or special equipments . Hematoma block is not compared with IV analgesia in children with fractures of lower segment of limbs before. In view of the above, a study is to be undertaken to evaluate the effects of hematoma block and Intravenous analgesic for closed reduction of fractures and for immediate pain relief in individuals.


Eligibility

Sex: Both males and femalesMin Age: 7 YearssMax Age: 14 Yearss

Inclusion Criteria5

  • Age between 7-14 years. Simple/closed fracture pattern.
  • Fractures of the forearm or shin bone.
  • Fracture duration less than 24 hours.
  • Parents Consent.
  • Childs Assent.

Exclusion Criteria3

  • Children with any co morbid disease, intra-articular, and epiphyseal fractures.
  • Un-displaced forearm and shin bone fractures which do not require manipulation.
  • Patients with multiple fractures.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Hematoma block and intravenous analgesia are the two interventions which will be administered by the Surgeon. Patients will be randomized to one of the groups. Each patient will only recieve one inter

Hematoma block and intravenous analgesia are the two interventions which will be administered by the Surgeon. Patients will be randomized to one of the groups. Each patient will only recieve one intervention. The intervention will be administered immediately before the fracture reduction. Hematoma block: Fracture hematoma will be injected with 2% lignocaine in a dose of 0.5 ml/kg. Intravenous analgesia: Injection Ketorolac (Toradol) will be injected in the Cubital vein of the contralateral limb in a dose of 0.2 ml/kg.


Locations(1)

Khyber Pakhtunkhwa, Pakistan

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12620001138976


Related Trials